Post Date December, 03 2023
According to a report published in the latest issue of the journal Nature Medicine, DNA extracted from healthy cells has been used to develop a new vaccine. This vaccine has a cure rate of up to 80% in mice with prostate cancer.
Researchers believe that this method may be applicable to the development of other cancer vaccines, and have begun research on melanoma vaccines. The British Cancer Research Council says this is a significant scientific development, but vaccines still need to be tested in humans. Developing a cancer vaccine is not a new initiative. Unlike traditional vaccines, which prevent diseases, cancer vaccines achieve therapeutic effects by promoting the autoimmune system to attack tumors that have already been generated.
The study, conducted by the University of Leeds in the United Kingdom and a clinic in the United States, involved decomposing DNA from healthy prostate cells and implanting a virus. The virus continues to infect experimental mice. Prostate DNA causes this virus to generate multiple prostate antigens, and when the immune system resists the virus, it learns to attack prostate cancer cells. It is crucial that healthy prostate cells and other body parts are not affected.
Scientists have achieved an 80% cure rate for prostate tumors in the laboratory using only nine injections in a single course, but researchers say it will still take years for the vaccine to begin human trials.
(Intern Editor: Xie Yunsheng)
